Click here to get full coverage on Insider Purchase: Chief Executive Officer of $NVCR Buys 81,550 Shares - Quiver Quantitative

Insider Purchase: Chief Executive Officer of $NVCR Buys 81,550 Shares  Quiver Quantitative

Insider Purchase: Chief Executive Officer of $NVCR Buys 81,550 Shares - Quiver Quantitative

Click here to get full coverage on Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail

Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR)  The Globe and Mail

Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail

Click here to get full coverage on NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st

NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard  simplywall.st

NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st

Click here to get full coverage on Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance

Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change?  Yahoo Finance

Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance

Click here to get full coverage on Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - Sahm

Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy?  Sahm

Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - Sahm

Click here to get full coverage on H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $42  富途牛牛

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛

Click here to get full coverage on Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy - Stock Titan

Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy  Stock Titan

Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy - Stock Titan

Click here to get full coverage on Behavioral Patterns of NVCR and Institutional Flows - news.stocktradersdaily.com

Behavioral Patterns of NVCR and Institutional Flows  news.stocktradersdaily.com

Behavioral Patterns of NVCR and Institutional Flows - news.stocktradersdaily.com

Click here to get full coverage on NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges - Yahoo Finance

NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges  Yahoo Finance

NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges - Yahoo Finance

Click here to get full coverage on NovoCure Limited Stock (NVCR) Opinions on FDA Approval of Optune Lua Device - Quiver Quantitative

NovoCure Limited Stock (NVCR) Opinions on FDA Approval of Optune Lua Device  Quiver Quantitative

NovoCure Limited Stock (NVCR) Opinions on FDA Approval of Optune Lua Device - Quiver Quantitative

Click here to get full coverage on NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?  Yahoo Finance

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $NVCR Given $23.0 Price Target | NVCR Stock News - Quiver Quantitative

New Analyst Forecast: $NVCR Given $23.0 Price Target | NVCR Stock News  Quiver Quantitative

New Analyst Forecast: $NVCR Given $23.0 Price Target | NVCR Stock News - Quiver Quantitative

Click here to get full coverage on Investors Give NovoCure Limited (NASDAQ:NVCR) Shares A 27% Hiding - simplywall.st

Investors Give NovoCure Limited (NASDAQ:NVCR) Shares A 27% Hiding  simplywall.st

Investors Give NovoCure Limited (NASDAQ:NVCR) Shares A 27% Hiding - simplywall.st

Click here to get full coverage on NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance

NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges  Yahoo Finance

NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance

Click here to get full coverage on NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - Yahoo Finance

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial  Yahoo Finance

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - Yahoo Finance

Click here to get full coverage on NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo - Yahoo Finance

NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo  Yahoo Finance

NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo - Yahoo Finance

Click here to get full coverage on NovoCure (NVCR): Evaluating Valuation as Share Price Stabilizes After Recent Volatility - Yahoo Finance

NovoCure (NVCR): Evaluating Valuation as Share Price Stabilizes After Recent Volatility  Yahoo Finance

NovoCure (NVCR): Evaluating Valuation as Share Price Stabilizes After Recent Volatility - Yahoo Finance

Click here to get full coverage on Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) - Yahoo Finance

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)  Yahoo Finance

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) - Yahoo Finance

Click here to get full coverage on NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed? - Yahoo Finance

NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed?  Yahoo Finance

NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha

NovoCure's Wearable Oncology Edge And Compelling Valuation  Seeking Alpha

NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha

Click here to get full coverage on What Makes NovoCure (NVCR) a New Buy Stock - Yahoo Finance

What Makes NovoCure (NVCR) a New Buy Stock  Yahoo Finance

What Makes NovoCure (NVCR) a New Buy Stock - Yahoo Finance

Click here to get full coverage on NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum  Seeking Alpha

NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha

Click here to get full coverage on Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference - Business Wire

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference  Business Wire

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference - Business Wire

Click here to get full coverage on 15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan

15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial  Stock Titan

15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan

Click here to get full coverage on NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st

NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential  simplywall.st

NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st

Click here to get full coverage on How (NVCR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

How (NVCR) Movements Inform Risk Allocation Models  news.stocktradersdaily.com

How (NVCR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

Click here to get full coverage on NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus

NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat  GuruFocus

NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus

Click here to get full coverage on NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer - Nasdaq

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer  Nasdaq

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer - Nasdaq

Click here to get full coverage on Novocure to Report Third Quarter 2025 Financial Results - Business Wire

Novocure to Report Third Quarter 2025 Financial Results  Business Wire

Novocure to Report Third Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Breakthrough Pancreatic Cancer Treatment: Novocure's TTFields Therapy Seeks FDA Approval After Success - Stock Titan

Breakthrough Pancreatic Cancer Treatment: Novocure's TTFields Therapy Seeks FDA Approval After Success  Stock Titan

Breakthrough Pancreatic Cancer Treatment: Novocure's TTFields Therapy Seeks FDA Approval After Success - Stock Titan

Click here to get full coverage on NovoCure Appoints Frank Leonard as New CEO - The Globe and Mail

NovoCure Appoints Frank Leonard as New CEO  The Globe and Mail

NovoCure Appoints Frank Leonard as New CEO - The Globe and Mail

Click here to get full coverage on NovoCure (NASDAQ:NVCR) Stock Price Up 7% - Time to Buy? - MarketBeat

NovoCure (NASDAQ:NVCR) Stock Price Up 7% - Time to Buy?  MarketBeat

NovoCure (NASDAQ:NVCR) Stock Price Up 7% - Time to Buy? - MarketBeat

Click here to get full coverage on H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38  富途牛牛

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛

Click here to get full coverage on NovoCure (NVCR) Q3 2025 Earnings Call Transcript - The Globe and Mail

NovoCure (NVCR) Q3 2025 Earnings Call Transcript  The Globe and Mail

NovoCure (NVCR) Q3 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus

Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta  GuruFocus

Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus

Click here to get full coverage on Novocure (NVCR) Faces Downgrade and New Price Target Amid Challe - GuruFocus

Novocure (NVCR) Faces Downgrade and New Price Target Amid Challe  GuruFocus

Novocure (NVCR) Faces Downgrade and New Price Target Amid Challe - GuruFocus

Click here to get full coverage on Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Nasdaq

Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics  Nasdaq

Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Nasdaq

Click here to get full coverage on NovoCure: Loading Up On Growth Catalysts - Seeking Alpha

NovoCure: Loading Up On Growth Catalysts  Seeking Alpha

NovoCure: Loading Up On Growth Catalysts - Seeking Alpha

Click here to get full coverage on Novocure Announces Upcoming Investor Events - Business Wire

Novocure Announces Upcoming Investor Events  Business Wire

Novocure Announces Upcoming Investor Events - Business Wire

Click here to get full coverage on 2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts - The Motley Fool

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts  The Motley Fool

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts - The Motley Fool

Click here to get full coverage on 8-Month Survival Boost: Novocure's Optune Lua Device Approved in Japan for Advanced Lung Cancer Treatment - Stock Titan

8-Month Survival Boost: Novocure's Optune Lua Device Approved in Japan for Advanced Lung Cancer Treatment  Stock Titan

8-Month Survival Boost: Novocure's Optune Lua Device Approved in Japan for Advanced Lung Cancer Treatment - Stock Titan

Click here to get full coverage on Day 5 of Loss Streak for NovoCure Stock with -34% Return (vs. -63% YTD) [7/30/2025] - Trefis

Day 5 of Loss Streak for NovoCure Stock with -34% Return (vs. -63% YTD) [7/30/2025]  Trefis

Day 5 of Loss Streak for NovoCure Stock with -34% Return (vs. -63% YTD) [7/30/2025] - Trefis

Click here to get full coverage on Novocure Reports Second Quarter 2025 Financial Results | NVCR St - GuruFocus

Novocure Reports Second Quarter 2025 Financial Results | NVCR St  GuruFocus

Novocure Reports Second Quarter 2025 Financial Results | NVCR St - GuruFocus

Click here to get full coverage on NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR) - Seeking Alpha

NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR)  Seeking Alpha

NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR) - Seeking Alpha

Click here to get full coverage on Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - The Motley Fool

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why  The Motley Fool

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - The Motley Fool

Click here to get full coverage on Novocure: Steady Ahead of Key Milestones - The Motley Fool

Novocure: Steady Ahead of Key Milestones  The Motley Fool

Novocure: Steady Ahead of Key Milestones - The Motley Fool

Click here to get full coverage on NOVOCURE Earnings Results: $NVCR Reports Quarterly Earnings - Quiver Quantitative

NOVOCURE Earnings Results: $NVCR Reports Quarterly Earnings  Quiver Quantitative

NOVOCURE Earnings Results: $NVCR Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on NovoCure Limited 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2025-07-25 - Seeking Alpha

NovoCure Limited 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2025-07-25  Seeking Alpha

NovoCure Limited 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:NVCR) 2025-07-25 - Seeking Alpha

Click here to get full coverage on NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Nasdaq

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?  Nasdaq

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Nasdaq

Click here to get full coverage on Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly?  simplywall.st

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

Click here to get full coverage on NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say  Nasdaq

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq

Click here to get full coverage on Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight  GuruFocus

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus

Click here to get full coverage on NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving Average - Time to Sell? - MarketBeat

NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving Average - Time to Sell?  MarketBeat

NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving Average - Time to Sell? - MarketBeat

Click here to get full coverage on NovoCure Q3 2025 Earnings Preview - MSN

NovoCure Q3 2025 Earnings Preview - MSN

Click here to get full coverage on NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha

NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead  Seeking Alpha

NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha

Click here to get full coverage on New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use  Stock Titan

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

Click here to get full coverage on Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain - Business Wire

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain  Business Wire

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain - Business Wire

Click here to get full coverage on NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com

NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data  Investing.com

NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com

Click here to get full coverage on Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st

Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares  simplywall.st

Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st

Click here to get full coverage on Novocure Reports Third Quarter 2025 Financial Results - Business Wire

Novocure Reports Third Quarter 2025 Financial Results  Business Wire

Novocure Reports Third Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’ - Yahoo Finance

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’  Yahoo Finance

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’ - Yahoo Finance

Click here to get full coverage on Wells Fargo Downgrades Novocure(NVCR.US) to Hold Rating, Cuts Target Price to $14.5 - 富途牛牛

Wells Fargo Downgrades Novocure(NVCR.US) to Hold Rating, Cuts Target Price to $14.5  富途牛牛

Wells Fargo Downgrades Novocure(NVCR.US) to Hold Rating, Cuts Target Price to $14.5 - 富途牛牛

Click here to get full coverage on 2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - The Motley Fool

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon  The Motley Fool

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - The Motley Fool

Click here to get full coverage on NovoCure Ltd SEC 10-Q Report - TradingView — Track All Markets

NovoCure Ltd SEC 10-Q Report  TradingView — Track All Markets

NovoCure Ltd SEC 10-Q Report - TradingView — Track All Markets

Click here to get full coverage on Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance

Novocure Appoints Company President Frank Leonard as Chief Executive Officer  Yahoo Finance

Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance

Click here to get full coverage on Why NovoCure Stock Was Withering on Wednesday - The Motley Fool

Why NovoCure Stock Was Withering on Wednesday  The Motley Fool

Why NovoCure Stock Was Withering on Wednesday - The Motley Fool

Click here to get full coverage on H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com

H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data  Investing.com

NVCR

Price Chart

Key Statistics

Technicals

About NVCR

Latest News

Insider Purchase: Chief Executive Officer of $NVCR Buys 81,550 Shares - Quiver Quantitative

Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail

NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st

Advanced Charts

Top Gainers

Top Losers